Clinical trial
BREMEN Eye Drops Versus Combigan for Open-angle Glaucoma or Intraocular Hypertension
BREMEN Eye Drops Versus Combigan for Open-angle Glaucoma or Intraocular Hypertension
Brief Summary:
The purpose of this study is to evaluate the clinical efficacy of the BREMEN eye drops in the treatment of primary open-angle glaucoma or intraocular hypertension.
Study Type: Interventional (Clinical Trial)
Estimated Enrollment: 384 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Investigator)
Primary Purpose: Treatment
Official Title: Randomized Clinical Trial to Compare the Efficacy and Safety of BREMEN Eye Drops Versus Combigan in Subjects With Open Angle Glaucoma or Ocular Hypertension
Actual Study Start Date: February 1, 2021
Estimated Primary Completion Date: August 2022
Estimated Study Completion Date: February 2023
Arm:
- Experimental: BREMEN eye drops
- Active Comparator: Combigan®
| Category | Value |
|---|---|
| Study type(s) | Interventional |
| Estimated enrolment | 384 |
| Actual Study start date | 01 February 2021 |
| Estimated Study Completion Date | 01 February 2023 |